+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability

Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability

Drug Metabolism and Drug Interactions 28(1): 49-58

Acute muscle injury and potentially fatal rhabdomyolysis may occur with use of statins and certain interacting medications. This investigation assessed risk for myopathy in patients receiving treatment with a statin in combination with daptomycin, a medication also associated with muscle injury. Patients hospitalized from July 1, 2005, through June 30, 2010, who received simvastatin or rosuvastatin concurrently with daptomycin were identified and their medical records were examined. Patients were judged to have treatment-related muscle injury if their records contained evidence of myalgia with or without weakness and secondarily impaired mobility together with elevated creatine kinase (CK) levels. These assessments were compared with similar data from hospitalized patients who received a statin alone. A total of 52 patients received 66 courses of concurrent treatment with simvastatin or rosuvastatin and daptomycin. Of these, no patient (0%) met evidentiary requirements for diagnosis of myopathy or related complications. No patient (0%) developed muscle pain or discomfort and none developed markedly elevated CK levels. The incidence of asymptomatic elevations of CK in these simvastatin or rosuvastatin plus daptomycin recipients (9%) was statistically indistinguishable from the incidence of CK elevations found in a cohort of 105 inpatients who received simvastatin or rosuvastatin alone (21%; p=0.135). In patients receiving treatment with simvastatin or rosuvastatin and daptomycin, no symptoms or objective evidence of muscle injury attributable to a drug interaction were identified. These findings are consistent with data indicating that the myopathic effects of statins and daptomycin are incited by disparate and perhaps unique pharmacological mechanisms. Risk of muscle injury therefore appears to be no greater when a statin is administered with daptomycin than when either medication is used alone.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911723

Download citation: RISBibTeXText

PMID: 23314530

DOI: 10.1515/dmdi-2012-0033

Related references

Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. Sage Open Medicine 6: 2050312118798278-2050312118798278, 2018

Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. Basic & Clinical Pharmacology & Toxicology 96(4): 289-294, 2005

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. Journal of Pharmaceutical Sciences 106(5): 1439-1451, 2017

Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports. Drug Safety 36(1): 63-70, 2013

Comparison of the Drug-Drug Interaction Potential of Daptomycin in Combination with Rifampin in Healthy Adult Volunteers. Antimicrobial Agents and ChemoTherapy 62(12): -, 2018

Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research. Journal of Biomolecular Screening 18(9): 1072-1083, 2014

Interaction of drug metabolism with the other elements of drug safety evaluation. Drug Metabolism Reviews 4(1): 115-133, 1975

An evaluation of the non-invasive faecal pellet assessment method as an early drug discovery screen for gastrointestinal liability. Journal of Pharmacological and Toxicological Methods 68(1): 123-136, 2014

Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. European Journal of Pharmaceutical Sciences 47(1): 244-255, 2013

Safety evaluation and drug development based on biological fate of drugs -efforts made to overcome drug interaction in drug development-. Drug Metabolism and Pharmacokinetics 17(5): 379-394, 2004

Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
. International Journal of Clinical Pharmacology and Therapeutics 54(12): 935-949, 2016

The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins. Expert Opinion on PharmacoTherapy 2(7): 1119-1127, 2001

Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrobial Agents and ChemoTherapy 58(6): 3177-3181, 2015

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharmaceutical Research 29(7): 1960-1976, 2012

When Worlds Collide: Biotechnology meets Organic Farming in Hoffman v Monsanto: Biotechnology--Organic farming--Liability--Negligence--Strict liability/Rylands v Fletcher--Nuisance--Trespass--Statutory liability--Economic damage--Litigating the safety of genetically modified organisms--Patent rights and responsibility--Access to information--Environmental impact assessment--Sustainable development law. Journal of Environmental Law 18(3): 459-477, 2006